Pharmaceutical - Pricing

Filter

Current filters:

Pricing

Popular Filters

1 to 25 of 605 results

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

20-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products,…

Federal Joint CommitteeGermanyJakaviMyelofibrosisNovartisOncologyPharmaceuticalPricingRare diseasesRegulation

IQWiG again turns down Eisai’s epilepsy drug Fycompa

IQWiG again turns down Eisai’s epilepsy drug Fycompa

17-08-2014

The German Institute for Quality and Efficiency in Healthcare (IQWiG) has said that epilepsy drug Fycompa…

EisaiEpilepsyFycompaGermanyNeurologicalPharmaceuticalPricingRegulation

New Zealand to fund Vidaza and Revlimid

New Zealand to fund Vidaza and Revlimid

13-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC says it has approved a proposal for funding…

Celgene Corp.FinancialHealthcareNew ZealandPharmaceuticalPricingRevlimidVidaza

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

13-08-2014

“The National Institute for Health and Care Excellence’s recent rejection of Kadcyla, Roche’s latest…

KadcylaOncologyPharmaceuticalPricingRegulationRocheUK

Ukraine may face drugs shortage this year

Ukraine may face drugs shortage this year

11-08-2014

Ukraine plans to ban pharmaceutical imports from Russia, except 20 vital drugs, the analogues of which…

Markets & MarketingPharmaceuticalPoliticsPricingRussiaUkraine

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

08-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGerman Institute for Quality and EfficiencyGermanyNovo NordiskPharmaceuticalPricingRegulationTresiba

NICE disappointed by Roche’s decision on Kadcyla pricing

NICE disappointed by Roche’s decision on Kadcyla pricing

08-08-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) said this morning…

Breast cancerCancerKadcylaNational Health ServiceOncologyPharmaceuticalPricingRegulationRocheUK

NICE comes back with different views on Tarceva and Iressa for NSCLC

NICE comes back with different views on Tarceva and Iressa for NSCLC

07-08-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is consulting again…

AstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

PhRMA comments on Medicare Rights Center paper

25-07-2014

“Finding viable solutions to contain Medicare costs is critically important, but imposing price controls…

FinancialHealthcarePharmaceuticalPricingUSA

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

21-07-2014

International medical humanitarian organization Médecins Sans Frontières has said that high prices…

Anti-viralsAntiretroviral drugHIVHIV/AIDSMSFPharmaceuticalPricing

Attractions and challenges of Poland’s pharmaceutical market

Attractions and challenges of Poland’s pharmaceutical market

17-07-2014

Not only is Poland the largest pharmaceutical market in the Central & Eastern Europe region and the sixth…

HealthcareMarkets & MarketingPharmaceuticalPolandPricing

The EMA’s scientific advice to pharma companies is a conflict of interest, says industry coalition

The EMA’s scientific advice to pharma companies is a conflict of interest, says industry coalition

15-07-2014

A coalition of major European medicines advocates has criticized the European Medicines Agency for providing…

EuropeEuropean Medicines AgencyHealth technology assessment bodiesPharmaceuticalPricingRegulation

Multinational and Indian drugmakers to face another price cap

Multinational and Indian drugmakers to face another price cap

15-07-2014

In a major blow to drug companies, India's National Pharmaceutical Pricing Authority (NPPA) has decided…

IndiaNational Pharmaceutical Pricing AuthorityPharmaceuticalPricing

UK cancer patients face increasing coverage restriction, US report shows

UK cancer patients face increasing coverage restriction, US report shows

11-07-2014

New US research released yesterday quantifies the extent to which centralized value assessments by the…

OncologyPharmaceuticalPricingRegulationUK

Orphan drug approvals rise, but high costs pose challenges for patients

Orphan drug approvals rise, but high costs pose challenges for patients

10-07-2014

Although the pace of approvals for new orphan drugs - medicines that treat relatively rare conditions…

EuropePharmaceuticalPricingRare diseasesRegulationUSA

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Report: Why pharmaceutical prices drop once drugs are off-patent

Report: Why pharmaceutical prices drop once drugs are off-patent

07-07-2014

The USA-based Pacific Research Institute has released a new report, titled The Economics of Pharmaceutical…

GlobalPatentsPharmaceuticalPricing

Further Indian drug price cuts, and price control categorization likely

30-06-2014

In order to make drugs more affordable to the country’s public, the Indian government is likely to…

FinancialIndiaPharmaceuticalPoliticsPricing

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Price cuts mean Australia’s PBS is sustainable, trade group argues

Price cuts mean Australia’s PBS is sustainable, trade group argues

20-06-2014

Yet more price cuts announced yesterday to come into effect on October 1 for 300 medicines reaffirms…

AustraliaHealthcarePharmaceuticalPricing

1 to 25 of 605 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top